Keywords: Amgen, Xgeva. UK, NICE, Bone metastases

UK's NICE continues to back Amgen's Xgeva for most cancer patients with bone metastases

Article | 17 August 2012

Print This

In a final draft guidance issued today, (August 17), the National Institute for Health and Clinical Excellence (NICE), the UK’ ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in